Novartis has completed the spinoff of its generics and biosimilars business, Sandoz, with shares trading at 24 Swiss Francs on the SIX Swiss Exchange. Novartis has been focusing on becoming a "pure play innovative medicines company" and has recently completed several major transactions. Sandoz, as an independent company, plans to focus on growing its generics and biosimilars business, with a pipeline of 25 biologics projects. The company expects around $3 billion in sales from its new pipeline, with half of the growth coming from North America.

The post Novartis unit Sandoz starts trading at 24 Swiss francs after completing spinoff appeared first on Balanced News Summary.